Oramed Pharmaceuticals Inc.
ORMP· Nasdaq
ORMPOramed Pharmaceuticals Inc.
Filed Apr 4, 2012 · 10-Q · 35 days after period end · 0001178913-12-001000
| Metric | Q2 2012 | Q2 2011 |
|---|---|---|
| Net Income | -$985.38K | -$642.79K |
| EPS Diluted | $0.17 | $0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
ended Feb 29, 2012 · filed Apr 4, 2012 · 35 d after period end
